Skip to main content
Fig. 2 | Molecular Medicine

Fig. 2

From: Improvement of ACK1-targeted therapy efficacy in lung adenocarcinoma using chloroquine or bafilomycin A1

Fig. 2

Clinical significance of the risk signature in the TCGA-LUAD cohort and validation in GEO cohorts. A The construction of a nomogram by integrating risk score and clinical stage. B The calibration plots compare the observed (y-axis) and predicated (x-axis) 1-, 3- and 5-year survival. C Decision curve analysis revealed that the combination of the risk score and TNM stage improved net benefit at any given threshold. The predicting accuracy of the 23-gene signature was tested in 495 patients with LUAD collected from GSE31210, GSE37745, and GSE50081 cohorts, by plotting ROC (D) and Kaplan–Meier survival curves (E)

Back to article page

Molecular Medicine

ISSN: 1528-3658